EP4687860A1 — Esketamine for use in the treatment of depression
Assigned to Janssen Pharmaceutica NV · Expires 2026-02-11 · 0y expired
What this patent protects
The present invention is directed to methods and dosing regimens for the treatment of treatment resistant depression in a patient that has had 2 or more prior treatment failures and is experiencing inadequate symptom relief from the combination of an antidepressant and adjunctive…
USPTO Abstract
The present invention is directed to methods and dosing regimens for the treatment of treatment resistant depression in a patient that has had 2 or more prior treatment failures and is experiencing inadequate symptom relief from the combination of an antidepressant and adjunctive treatment with quetiapine.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.